MX2012003408A - Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases. - Google Patents

Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases.

Info

Publication number
MX2012003408A
MX2012003408A MX2012003408A MX2012003408A MX2012003408A MX 2012003408 A MX2012003408 A MX 2012003408A MX 2012003408 A MX2012003408 A MX 2012003408A MX 2012003408 A MX2012003408 A MX 2012003408A MX 2012003408 A MX2012003408 A MX 2012003408A
Authority
MX
Mexico
Prior art keywords
abt
crystalline forms
solvates
related diseases
protein related
Prior art date
Application number
MX2012003408A
Other languages
Spanish (es)
Inventor
Thomas B Borchardt
Paul J Brackemeyer
Geoff G Z Zhang
Nathaniel D Catron
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2012003408A publication Critical patent/MX2012003408A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
MX2012003408A 2009-09-20 2010-09-15 Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases. MX2012003408A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24405109P 2009-09-20 2009-09-20
PCT/US2010/048949 WO2011034934A1 (en) 2009-09-20 2010-09-15 Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases

Publications (1)

Publication Number Publication Date
MX2012003408A true MX2012003408A (en) 2012-08-03

Family

ID=43064468

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003408A MX2012003408A (en) 2009-09-20 2010-09-15 Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases.

Country Status (15)

Country Link
US (2) US8362014B2 (en)
EP (1) EP2477972A1 (en)
JP (2) JP2013505249A (en)
KR (1) KR20120085781A (en)
CN (2) CN105820138A (en)
AU (1) AU2010295717B2 (en)
BR (1) BR112012006252A2 (en)
CA (1) CA2771984A1 (en)
IL (1) IL218403A0 (en)
MX (1) MX2012003408A (en)
NZ (1) NZ598461A (en)
RU (1) RU2551376C2 (en)
TW (1) TWI488853B (en)
WO (1) WO2011034934A1 (en)
ZA (1) ZA201202891B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102209729B (en) * 2008-11-07 2016-05-25 安进研发（慕尼黑）股份有限公司 Treatment of acute lymphoblastic leukemia in children
RS58827B1 (en) 2008-11-07 2019-07-31 Amgen Res Munich Gmbh Treatment of acute lymphoblastic leukemia
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
TWI532484B (en) * 2009-06-08 2016-05-11 艾伯維有限公司 Solid dispersions containing an apoptosis-promoting agent
TWI471321B (en) * 2009-06-08 2015-02-01 亞培公司 Oral pharmaceutical dosage form of BCL-2 group inhibitor
CN105820138A (en) 2009-09-20 2016-08-03 Abbvie 公司 ABT-263 crystalline forms and solvates for use in treating BCL-2 protein related diseases
JP5779591B2 (en) * 2009-12-22 2015-09-16 アッヴィ・インコーポレイテッド ABT-263 capsule
UA113500C2 (en) 2010-10-29 2017-02-10 MEL EXTRUSION SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
PL2958916T3 (en) * 2013-02-21 2019-01-31 Pfizer Inc. Solid forms of a selective cdk4/6 inhibitor
WO2014160071A1 (en) 2013-03-14 2014-10-02 St. Jude Children's Research Hospital Methods and compositions for the treatment of glutamine-addicted cancers
CA2909380A1 (en) * 2013-04-21 2014-10-30 Yeda Research And Development Co. Ltd. Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w
EP3099380B1 (en) 2014-01-28 2021-08-11 Buck Institute for Research on Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
WO2015157120A1 (en) * 2014-04-06 2015-10-15 Abraxis Bioscience, Llc Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
TW201639573A (en) 2015-02-03 2016-11-16 吉李德科學股份有限公司 Combination therapies for treating cancers
WO2018085069A1 (en) 2016-11-03 2018-05-11 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
TR201703149A2 (en) * 2017-03-01 2018-09-21 Univ Yeditepe CHEMOTHERAPIC MEDICINE COMPOSITION
CN108727387B (en) * 2018-07-25 2021-03-16 天津大学 Ibrutinib isopropyl acetate solvent compound and preparation method thereof
CN109053738B (en) * 2018-08-29 2020-10-16 浙江工业大学 A kind of solvate of ibrutinib and preparation method thereof
JP7417356B2 (en) 2019-01-25 2024-01-18 株式会社ソニー・インタラクティブエンタテインメント robot control system
US11285159B2 (en) 2019-11-05 2022-03-29 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2713507A (en) 1948-10-04 1955-07-19 Garlinghouse Brothers Concrete bucket
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7075365B1 (en) 2004-04-22 2006-07-11 Altera Corporation Configurable clock network for programmable logic device
PT1888550E (en) * 2005-05-12 2014-09-03 Abbvie Bahamas Ltd Apoptosis promoters
EP2061560A2 (en) * 2006-09-05 2009-05-27 Abbott Laboratories Bcl inhibitors for treating platelet excess
JP4202380B2 (en) * 2006-10-17 2008-12-24 シャープ株式会社 Image forming apparatus
MX2010006260A (en) 2007-12-06 2010-08-23 Abbott Lab Oral compositions of abt-263 for treating cancer.
CN101220008B (en) * 2008-01-21 2011-04-27 中国科学院广州生物医药与健康研究院 The synthetic method of compound ABT-263
US8168784B2 (en) * 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
US8140876B2 (en) * 2009-01-16 2012-03-20 International Business Machines Corporation Reducing power consumption of components based on criticality of running tasks independent of scheduling priority in multitask computer
JP2010259520A (en) 2009-04-30 2010-11-18 Motoji Ono Conveyor structure, tread mill and conveyor
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100297194A1 (en) 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20110047552A1 (en) * 2009-05-11 2011-02-24 Raytheon Bbn Technologies Corp. Energy-aware process environment scheduler
US8291422B2 (en) * 2009-05-11 2012-10-16 Bbn Technologies Corp. Energy-aware computing environment scheduler
CN105820138A (en) 2009-09-20 2016-08-03 Abbvie 公司 ABT-263 crystalline forms and solvates for use in treating BCL-2 protein related diseases
CN101798292A (en) * 2010-03-29 2010-08-11 无锡好芳德药业有限公司 Method for preparing novel Bc1-2 protein inhibitor derived from ABT-263

Also Published As

Publication number Publication date
RU2012115851A (en) 2013-10-27
IL218403A0 (en) 2012-04-30
CA2771984A1 (en) 2011-03-24
AU2010295717B2 (en) 2014-09-11
US8362014B2 (en) 2013-01-29
TWI488853B (en) 2015-06-21
ZA201202891B (en) 2013-09-25
JP2013505249A (en) 2013-02-14
CN102695702A (en) 2012-09-26
JP2015232006A (en) 2015-12-24
AU2010295717A1 (en) 2012-03-22
NZ598461A (en) 2013-12-20
BR112012006252A2 (en) 2017-05-23
TW201116526A (en) 2011-05-16
US20110071151A1 (en) 2011-03-24
KR20120085781A (en) 2012-08-01
US20110294811A1 (en) 2011-12-01
EP2477972A1 (en) 2012-07-25
WO2011034934A1 (en) 2011-03-24
US8513243B2 (en) 2013-08-20
CN105820138A (en) 2016-08-03
RU2551376C2 (en) 2015-05-20

Similar Documents

Publication Publication Date Title
MX2012003408A (en) Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases.
MX2011011511A (en) Salt of abt-263 and solid-state forms thereof.
PH12015500297A1 (en) Adoptosis-inducing agents for the treatment of cancer and immune and automoimmune disease
UA108193C2 (en) APOPTOZINDUCE FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTO-IMMUNE DISEASES
MX2011007684A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases.
PH12012501071A1 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
PH12015502792A1 (en) Crystalline bromodomain inhibitors
UA107706C2 (en) APOPTOSIS-INDUCTIVE MEANS FOR TREATMENT OF CANCER AND IMMUNE AND AUTO-IMMUNE DISEASES
WO2010083441A3 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
MX2009000285A (en) Substituted piperidines that increase p53 activity and the uses thereof.
PH12016501126A1 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA94097C2 (en) Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors
NZ598694A (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
TNSN07093A1 (en) Bicyclic amides as kinase inhibitors
PL1687305T3 (en) 1h-imidazoquinoline derivatives as protein kinase inhibitors
EA017091B9 (en) Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
CL2011000124A1 (en) Compounds derived from 3-aryl-4-heterocyclyl-pyrazoles, protein kinase b-raf inhibitors; In vitro inhibition method of protein kinase b-raf; pharmaceutical composition; pharmaceutical combination product; and its use for the treatment of cancer.
NZ596047A (en) Stabilized lipid formulation of apoptosis promoter
MX2009006327A (en) Heterocycle compounds and methods of use thereof.
MX2014003408A (en) N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydro-cyclopenta[e] [1,3]oxazin-4-yl)-phenyl)-amides as bace1 inhibitors.
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
DE602007011975D1 (en) THIADIAZOL DERIVATIVES FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
MY150931A (en) Substituted oxazolidinones and their use
MX2012007325A (en) Abt-263 capsule.
UA107655C2 (en) SELECTIVE BCL-2 ANTIAPOPTIC PROTEIN INHIBITORS FOR TREATMENT OF CANCER AND IMMUNE DISEASES

Legal Events

Date Code Title Description
GB Transfer or rights